ScoreWhy is Krystal Biotech, Inc. ?
1
The company has declared Positive results for the last 7 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 195.4 MM
- NET PROFIT(HY) At USD 74.07 MM has Grown at 80.08%
- ROCE(HY) Highest at 15.61%
2
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Krystal Biotech, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Krystal Biotech, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Krystal Biotech, Inc.
19.35%
0.51
44.43%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
224.57%
EBIT Growth (5y)
52.40%
EBIT to Interest (avg)
-32.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.21
Tax Ratio
10.19%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
7.24%
ROE (avg)
4.74%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
4.02
EV to EBIT
25.02
EV to EBITDA
23.83
EV to Capital Employed
9.05
EV to Sales
10.02
PEG Ratio
0.25
Dividend Yield
NA
ROCE (Latest)
36.18%
ROE (Latest)
14.98%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 195.4 MM
NET PROFIT(HY)
At USD 74.07 MM has Grown at 80.08%
ROCE(HY)
Highest at 15.61%
RAW MATERIAL COST(Y)
Fallen by -2.64% (YoY
CASH AND EQV(HY)
Highest at USD 1,298.83 MM
NET SALES(Q)
Highest at USD 96.04 MM
PRE-TAX PROFIT(Q)
At USD 46.77 MM has Grown at 63.86%
-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Krystal Biotech, Inc.
Operating Cash Flow
Highest at USD 195.4 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
At USD 74.07 MM has Grown at 80.08%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Sales
Highest at USD 96.04 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 96.04 MM has Grown at 36.65%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 46.77 MM has Grown at 63.86%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Cash and Eqv
Highest at USD 1,298.83 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -2.64% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
